
|Podcasts|December 14, 2022
The Cutaneous Connection: JAK Inhibitor Safety for Treating AD
Author(s)Kaitlyn Bader, Associate Editor
In this episode, Christopher Bunick, MD, PhD, discusses a paper he recently co-authored, which explores JAK inhibitor safety compared to traditional systemic therapies for atopic dermatitis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
3
Dermatology Conferences and Meetings Calendar: December 2025
4
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
5


















